OC
PACB icon

Oppenheimer & Co’s Pacific Biosciences PACB Stock Holding History

Oppenheimer & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-43,920
Closed -$509K – 1464
2023
Q1 		$509K Sell
43,920
-568
-1% -$5.65K 0.01% 931
2022
Q4 		$364K Sell
44,488
-2,608
-6% -$22.5K 0.01% 1022
2022
Q3 		$273K Buy
47,096
+27,096
+135% +$155K 0.01% 1098
2022
Q2 		$88K Sell
20,000
-2,125
-10% -$12.9K ﹤0.01% 1341
2022
Q1 		$201K Hold
22,125
– – ﹤0.01% 1354
2021
Q4 		$452K Buy
+22,125
New +$534K 0.01% 1082
2021
Q3 		– Sell
-13,171
Closed -$461K – 1555
2021
Q2 		$461K Buy
13,171
+1,103
+9% +$32.1K 0.01% 1070
2021
Q1 		$402K Buy
+12,068
New +$422K 0.01% 1055
2020
Q4 		– Sell
-29,361
Closed -$290K – 1387
2020
Q3 		$290K Buy
+29,361
New +$169K 0.01% 996

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Oppenheimer & Co's PACB Position: Q2 2023 in Review

Oppenheimer & Co sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 43,920 shares — an estimated $509K sold.

Oppenheimer & Co first reported a position in PACB in Q3 2020 and held it in 9 quarters. The position peaked at $509K in Q1 2023. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Oppenheimer & Co reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 43,920 Pacific Biosciences shares in Q2 2023, an estimated $509K.
  • Oppenheimer & Co first reported a position in Pacific Biosciences in Q3 2020 and held it in 9 quarters.
  • Oppenheimer & Co's Pacific Biosciences position peaked at $509K in Q1 2023.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.